Evidence map›Paper›PMID 31022207›Full record

ArticlePloS one2019

Applying hydrodynamic pressure to efficiently generate induced pluripotent stem cells via reprogramming of centenarian skin fibroblasts.

Massoud Vosough, Francesco Ravaioli, Mihaela Zabulica, Miriam Capri, Paolo Garagnani, Claudio Franceschi, Julie Piccand, Marine R-C Kraus, Kristina Kannisto, Roberto Gramignoli and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Correction of a urea cycle defect after ex vivo gene editing of human hepatocytes.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Massoud VosoughDepartment of Stem Cells and Developmental Biology, Cell Science Research Centre, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Francesco RavaioliUniversity of Bologna, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy.ORCID 0000-0001-6976-8489
Mihaela ZabulicaDivision of Pathology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Miriam CapriUniversity of Bologna, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy.
Paolo GaragnaniUniversity of Bologna, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy.
Claudio FranceschiUniversity of Bologna, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy.
Julie PiccandNestlé Institute of Health Sciences, Stem Cells, Lausanne, Switzerland.ORCID 0000-0002-0719-8721
Marine R-C KrausNestlé Institute of Health Sciences, Stem Cells, Lausanne, Switzerland.ORCID 0000-0002-9782-0472
Kristina KannistoDivision of Pathology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Roberto GramignoliDivision of Pathology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Stephen C StromDivision of Pathology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Karolinska Institutet · SENestlé (Switzerland) · CHUniversity of Bologna · ITIstituto delle Scienze Neurologiche di Bologna · ITRoyan Institute · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Induced pluripotent stem cell (iPSC)-technology is an important platform in medicine and disease modeling. Physiological degeneration and disease onset are common occurrences in the aging population. iPSCs could offer regenerative medical options for age-related degeneration and disease in the elderly. However, reprogramming somatic cells from the elderly is inefficient when successful at all. Perhaps due to their low rates of replication in culture, traditional transduction and reprogramming approaches with centenarian fibroblasts met with little success. A simple and reproducible reprogramming process is reported here which enhances interactions of the cells with the viral vectors that leads to improved iPSC generation. The improved methods efficiently generates fully reprogrammed iPSC lines from 105-107 years old subjects in feeder-free conditions using an episomal, Sendai-Virus (SeV) reprogramming vector expressing four reprogramming factors. In conclusion, dermal fibroblasts from human subjects older than 100 years can be efficiently and reproducibly reprogrammed to fully pluripotent cells with minor modifications to the standard reprogramming procedures. Efficient generation of iPSCs from the elderly may provide a source of cells for the regeneration of tissues and organs with autologous cells as well as cellular models for the study of aging, longevity and age-related diseases.

Indexed as

Cellular ReprogrammingAdultAged, 80 and overAge FactorsCells, CulturedCellular Reprogramming TechniquesFibroblastsGenetic VectorsHumansHydrodynamicsInduced Pluripotent Stem CellsInfant, NewbornPrimary Cell CultureReproducibility of ResultsSendai virusSkin

Identifiers

PMID31022207
PMCPMC6483185
OpenAlexW2941997115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.